» Articles » PMID: 28462821

Aging of Bone Marrow- and Umbilical Cord-derived Mesenchymal Stromal Cells During Expansion

Overview
Journal Cytotherapy
Publisher Elsevier
Date 2017 May 3
PMID 28462821
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Background Aims: Mesenchymal stromal cells (MSCs) are used as experimental immunotherapy. Extensive culture expansion is necessary to obtain clinically relevant cell numbers, although the impact on MSCs stability and function is unclear. This study investigated the effects of long-term in vitro expansion on the stability and function of MSCs.

Methods: Human bone marrow-derived (bmMSCs) and umbilical cord-derived (ucMSCs) MSCs were in vitro expanded. During expansion, their proliferative capacity was examined. At passages 4, 8 and 12, analyses were performed to investigate the ploidy, metabolic stability, telomere length and immunophenotype. In addition, their potential to suppress lymphocyte proliferation and susceptibility to natural killer cell lysis was examined.

Results: BmMSCs and ucMSCs showed decreasing proliferative capacity over time, while their telomere lengths and mitochondrial activity remained stable. Percentage of aneuploidy in cultures was unchanged after expansion. Furthermore, expression of MSC markers and markers associated with stress or aging remained unchanged. Reduced capacity to suppress CD4 and CD8 T-cell proliferation was observed for passage 8 and 12 bmMSCs and ucMSCs. Finally, susceptibility of bmMSCs and ucMSCs to NK-cell lysis remained stable.

Conclusions: We showed that after long-term expansion, phenotype of bmMSCs and ucMSCs remains stable and cells exhibit similar immunogenic properties compared with lower passage cells. However, immunosuppressive properties of MSCs are reduced. These findings reveal the consequences of application of higher passage MSCs in the clinic, which will help increase the yield of therapeutic MSCs but may interfere with their efficacy.

Citing Articles

DNA Methyltransferase Inhibition by RG108 Improves Stemness and Multipotential Differentiation of Human Adipose Tissue-derived Stem Cells.

Asgharian R, Hashemi A, Javeri A, Taha M Iran J Biotechnol. 2024; 22(2):e3863.

PMID: 39220336 PMC: 11364923. DOI: 10.30498/ijb.2024.435096.3863.


Murine bone-derived mesenchymal stem cells undergo molecular changes after a single passage in culture.

Hughes A, Kuek V, Oommen J, Kotecha R, Cheung L Sci Rep. 2024; 14(1):12396.

PMID: 38811646 PMC: 11137146. DOI: 10.1038/s41598-024-63009-8.


Decoding Sepsis-Induced Disseminated Intravascular Coagulation: A Comprehensive Review of Existing and Emerging Therapies.

Unar A, Bertolino L, Patauner F, Gallo R, Durante-Mangoni E J Clin Med. 2023; 12(19).

PMID: 37834771 PMC: 10573475. DOI: 10.3390/jcm12196128.


Multi-omics analysis of human mesenchymal stem cells shows cell aging that alters immunomodulatory activity through the downregulation of PD-L1.

Gao Y, Chi Y, Chen Y, Wang W, Li H, Zheng W Nat Commun. 2023; 14(1):4373.

PMID: 37474525 PMC: 10359415. DOI: 10.1038/s41467-023-39958-5.


Mesenchymal Stem/Stromal Cell-Based Therapies in Systemic Rheumatic Disease: From Challenges to New Approaches for Overcoming Restrictions.

Lee B, Kwok S Int J Mol Sci. 2023; 24(12).

PMID: 37373308 PMC: 10299481. DOI: 10.3390/ijms241210161.